Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, and Outcomes from Japanese Nationwide Data (ICBMT 2026) - Oct 8, 2026 - Abstract #JS05-3; Pres time: Sep 18, 2026; 05:40 PM - 06:05 PM; Location: Room C(2F); "Among lymphoma subtypes, patients with mature B-cell lymphoma, most of whom had received rituximab, had the lowest 2-year incidence of PTLD at 0.35%. In this session, I will review Japanese nationwide data on the incidence, risk factors, and outcomes of PTLD after HSCT and discuss practical considerations for surveillance and management."
Clinical • Post-transplantation • Acute Graft versus Host Disease • Aplastic Anemia • B Cell Lymphoma • Bone Marrow Transplantation • Epstein-Barr Virus Infections • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Lymphoma • Non-Hodgkin's Lymphoma • Transplantation
|